These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Choueiri TK; Escudier B; Powles T; Tannir NM; Mainwaring PN; Rini BI; Hammers HJ; Donskov F; Roth BJ; Peltola K; Lee JL; Heng DYC; Schmidinger M; Agarwal N; Sternberg CN; McDermott DF; Aftab DT; Hessel C; Scheffold C; Schwab G; Hutson TE; Pal S; Motzer RJ; Lancet Oncol; 2016 Jul; 17(7):917-927. PubMed ID: 27279544 [TBL] [Abstract][Full Text] [Related]
3. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. Motzer R; Alekseev B; Rha SY; Porta C; Eto M; Powles T; Grünwald V; Hutson TE; Kopyltsov E; Méndez-Vidal MJ; Kozlov V; Alyasova A; Hong SH; Kapoor A; Alonso Gordoa T; Merchan JR; Winquist E; Maroto P; Goh JC; Kim M; Gurney H; Patel V; Peer A; Procopio G; Takagi T; Melichar B; Rolland F; De Giorgi U; Wong S; Bedke J; Schmidinger M; Dutcus CE; Smith AD; Dutta L; Mody K; Perini RF; Xing D; Choueiri TK; N Engl J Med; 2021 Apr; 384(14):1289-1300. PubMed ID: 33616314 [TBL] [Abstract][Full Text] [Related]
4. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. Choueiri TK; Eto M; Motzer R; De Giorgi U; Buchler T; Basappa NS; Méndez-Vidal MJ; Tjulandin S; Hoon Park S; Melichar B; Hutson T; Alemany C; McGregor B; Powles T; Grünwald V; Alekseev B; Rha SY; Kopyltsov E; Kapoor A; Alonso Gordoa T; Goh JC; Staehler M; Merchan JR; Xie R; Perini RF; Mody K; McKenzie J; Porta CG Lancet Oncol; 2023 Mar; 24(3):228-238. PubMed ID: 36858721 [TBL] [Abstract][Full Text] [Related]
5. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study. Motzer R; Porta C; Alekseev B; Rha SY; Choueiri TK; Mendez-Vidal MJ; Hong SH; Kapoor A; Goh JC; Eto M; Bennett L; Wang J; Pan JJ; Saretsky TL; Perini RF; He CS; Mody K; Cella D Lancet Oncol; 2022 Jun; 23(6):768-780. PubMed ID: 35489363 [TBL] [Abstract][Full Text] [Related]
6. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Armstrong AJ; Halabi S; Eisen T; Broderick S; Stadler WM; Jones RJ; Garcia JA; Vaishampayan UN; Picus J; Hawkins RE; Hainsworth JD; Kollmannsberger CK; Logan TF; Puzanov I; Pickering LM; Ryan CW; Protheroe A; Lusk CM; Oberg S; George DJ Lancet Oncol; 2016 Mar; 17(3):378-388. PubMed ID: 26794930 [TBL] [Abstract][Full Text] [Related]
7. Lenvatinib for the treatment of kidney cancer. Študentová H; Vitásková D; Melichar B Expert Rev Anticancer Ther; 2018 Jun; 18(6):511-518. PubMed ID: 29737893 [TBL] [Abstract][Full Text] [Related]
8. Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma. Glen H Future Oncol; 2016 Oct; 12(19):2195-204. PubMed ID: 27339111 [TBL] [Abstract][Full Text] [Related]
9. Lenvatinib in combination with everolimus in patients with advanced or metastatic renal cell carcinoma: A phase 1 study. Matsubara N; Naito Y; Nakano K; Fujiwara Y; Ikezawa H; Yusa W; Namiki M; Okude T; Takahashi S Int J Urol; 2018 Nov; 25(11):922-928. PubMed ID: 30129060 [TBL] [Abstract][Full Text] [Related]
10. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818 [TBL] [Abstract][Full Text] [Related]
11. Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma. Lee CH; Motzer RJ; Glen H; Michaelson MD; Larkin J; Minoshima Y; Kanekiyo M; Ikezawa H; Sachdev P; Dutcus CE; Funahashi Y; Voss MH Br J Cancer; 2021 Jan; 124(1):237-246. PubMed ID: 33024271 [TBL] [Abstract][Full Text] [Related]
12. Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study. Gaspar N; Venkatramani R; Hecker-Nolting S; Melcon SG; Locatelli F; Bautista F; Longhi A; Lervat C; Entz-Werle N; Casanova M; Aerts I; Strauss SJ; Thebaud E; Morland B; Nieto AC; Marec-Berard P; Gambart M; Rossig C; Okpara CE; He C; Dutta L; Campbell-Hewson Q Lancet Oncol; 2021 Sep; 22(9):1312-1321. PubMed ID: 34416158 [TBL] [Abstract][Full Text] [Related]
13. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Makker V; Rasco D; Vogelzang NJ; Brose MS; Cohn AL; Mier J; Di Simone C; Hyman DM; Stepan DE; Dutcus CE; Schmidt EV; Guo M; Sachdev P; Shumaker R; Aghajanian C; Taylor M Lancet Oncol; 2019 May; 20(5):711-718. PubMed ID: 30922731 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial. Ferolla P; Brizzi MP; Meyer T; Mansoor W; Mazieres J; Do Cao C; Léna H; Berruti A; Damiano V; Buikhuisen W; Grønbæk H; Lombard-Bohas C; Grohé C; Minotti V; Tiseo M; De Castro J; Reed N; Gislimberti G; Singh N; Stankovic M; Öberg K; Baudin E Lancet Oncol; 2017 Dec; 18(12):1652-1664. PubMed ID: 29074099 [TBL] [Abstract][Full Text] [Related]
15. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. Lee CH; Shah AY; Rasco D; Rao A; Taylor MH; Di Simone C; Hsieh JJ; Pinto A; Shaffer DR; Girones Sarrio R; Cohn AL; Vogelzang NJ; Bilen MA; Gunnestad Ribe S; Goksel M; Tennøe ØK; Richards D; Sweis RF; Courtright J; Heinrich D; Jain S; Wu J; Schmidt EV; Perini RF; Kubiak P; Okpara CE; Smith AD; Motzer RJ Lancet Oncol; 2021 Jul; 22(7):946-958. PubMed ID: 34143969 [TBL] [Abstract][Full Text] [Related]
16. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Motzer RJ; Rini BI; McDermott DF; Arén Frontera O; Hammers HJ; Carducci MA; Salman P; Escudier B; Beuselinck B; Amin A; Porta C; George S; Neiman V; Bracarda S; Tykodi SS; Barthélémy P; Leibowitz-Amit R; Plimack ER; Oosting SF; Redman B; Melichar B; Powles T; Nathan P; Oudard S; Pook D; Choueiri TK; Donskov F; Grimm MO; Gurney H; Heng DYC; Kollmannsberger CK; Harrison MR; Tomita Y; Duran I; Grünwald V; McHenry MB; Mekan S; Tannir NM; Lancet Oncol; 2019 Oct; 20(10):1370-1385. PubMed ID: 31427204 [TBL] [Abstract][Full Text] [Related]
17. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. Rini BI; Pal SK; Escudier BJ; Atkins MB; Hutson TE; Porta C; Verzoni E; Needle MN; McDermott DF Lancet Oncol; 2020 Jan; 21(1):95-104. PubMed ID: 31810797 [TBL] [Abstract][Full Text] [Related]
18. The Efficacy of Lenvatinib Plus Everolimus in Patients with Metastatic Renal Cell Carcinoma Exhibiting Primary Resistance to Front-Line Targeted Therapy or Immunotherapy. Hamieh L; Beck RL; Le VH; Hsieh JJ Clin Genitourin Cancer; 2020 Aug; 18(4):252-257.e2. PubMed ID: 32291161 [TBL] [Abstract][Full Text] [Related]
19. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. von Minckwitz G; Puglisi F; Cortes J; Vrdoljak E; Marschner N; Zielinski C; Villanueva C; Romieu G; Lang I; Ciruelos E; De Laurentiis M; Veyret C; de Ducla S; Freudensprung U; Srock S; Gligorov J Lancet Oncol; 2014 Oct; 15(11):1269-78. PubMed ID: 25273342 [TBL] [Abstract][Full Text] [Related]
20. A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC). Molina AM; Hutson TE; Larkin J; Gold AM; Wood K; Carter D; Motzer R; Michaelson MD Cancer Chemother Pharmacol; 2014 Jan; 73(1):181-9. PubMed ID: 24190702 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]